- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Quick take on Tesamorelin
Tesamorelin — sold under the brand name Egrifta — is a synthetic analog of natural GHRH (growth hormone-releasing hormone) with a slightly modified structure that resists enzymatic breakdown and extends half-life to roughly 30-40 minutes (compared to Sermorelin's 10-20 minutes). Developed by Theratechnologies and approved by the FDA in 2010, specifically for reducing visceral adipose tissue (VAT) in HIV patients with lipodystrophy — a condition where antiretroviral therapy caused abnormal fat accumulation in the abdomen. It's one of the few peptides in this category with both FDA approval and the clinical trial data to back up its specific use case.
Mechanism in plain English
Tesamorelin binds to GHRH receptors in the pituitary and stimulates natural, pulsatile GH release, which in turn raises IGF-1 and drives the metabolic effects. The pattern is physiological — your body releases its own GH in its own rhythm — but the extended half-life produces a stronger and longer pulse than Sermorelin. In clinical trials, the standout effect was preferential reduction of visceral (deep abdominal) fat while largely sparing subcutaneous fat.
What it's used for
People take it for one standout benefit: targeted visceral fat reduction. The FDA pivotal trials showed roughly 15-18% reduction in visceral fat after 26 weeks in HIV patients with lipodystrophy. This specificity for deep abdominal fat separates Tesamorelin from most other GH-axis compounds and makes it attractive for men over 40 with stubborn midsection accumulation — the metabolically dangerous fat around the organs. Secondary benefits include the standard GH-axis lineup: improved sleep, recovery, and skin quality.
Upsides and downsides
Main upside — FDA-approved with clinical trial data specifically validating visceral fat reduction, which is both the hardest fat to lose through diet and exercise alone and the fat most associated with cardiovascular and metabolic disease. This makes Tesamorelin genuinely unique in the GHRH analog category.
Main downside — cost and injection frequency. Brand-name Egrifta is expensive, daily dosing is required, and like other GH secretagogues it carries risks around insulin resistance, joint pain, and water retention at therapeutic doses.
Typical protocol
Protocols run 1-2 mg subcutaneously once daily, usually in the evening, on an empty stomach. Cycles typically run 3-6 months. Often stacked with Ipamorelin for synergistic GH release, similar to the Mod GRF 1-29 + Ipamorelin combination but with Tesamorelin's longer pulse and visceral fat specificity.
Who should skip it
- Anyone with active cancer.
- Anyone with diabetic retinopathy.
- Anyone with a pituitary disorder.
- Anyone with severe insulin resistance.
Regulatory status
Banned by WADA under category S2 as a growth hormone secretagogue. Legally prescribable in the US through anti-aging and HIV medicine channels for its approved indication.
In the late 1990s, the introduction of highly active antiretroviral therapy (HAART) transformed HIV from a death sentence into a manageable chronic disease. Patients who would have died within years began living decades. It was one of the great medical achievements of modern history.
But these life-saving medications came with a strange and disfiguring side effect: HIV-associated lipodystrophy. Patients on HAART often developed bizarre fat redistribution — arms, legs, and face becoming emaciated while massive amounts of fat accumulated in the abdomen around internal organs (visceral adipose tissue). Beyond the cosmetic distress, this visceral fat was metabolically dangerous, driving dyslipidemia, insulin resistance, and cardiovascular risk. It was also a visible marker of HIV status in an era when that still carried significant social stigma.
No drug existed to treat this specific fat pattern until a Montreal-based company called Theratechnologies developed a modified GHRH analog they called TH9507. After extensive clinical trials, the FDA approved it in November 2010 under the brand name Egrifta — making it the first and still only medication specifically approved for HIV-associated lipodystrophy. Its generic name is Tesamorelin.
What makes Tesamorelin special in the peptide world: it's the only GHRH analog with full FDA approval. While Sermorelin is FDA-approved for pediatric GHD and CJC-1295/Mod GRF 1-29 exist in the research chemical gray zone, Tesamorelin is a legitimate prescription medication sold at pharmacies, covered by insurance (for approved indications), and supported by robust clinical trial data. It also happens to be extraordinarily good at reducing visceral fat — which explains why it's the most-pursued GHRH analog for off-label body composition applications.
Tesamorelin: what it is and how it works in a nutshell
Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) — specifically, the full GHRH(1-44) sequence with a trans-3-hexenoic acid group conjugated to the N-terminal tyrosine. This N-terminal modification dramatically improves enzymatic stability while preserving GHRH receptor activity [1].
This distinguishes Tesamorelin from most other GHRH analogs on the market:
- Sermorelin is GHRH(1-29) with no modification — the shortest functional fragment
- Modified GRF 1-29 / CJC-1295 is GHRH(1-29) with 4 amino acid substitutions for stability
- Tesamorelin is the full GHRH(1-44) with a trans-3-hexenoic acid group at the N-terminus
The result is a peptide that closely resembles natural GHRH in structure but is substantially more stable, with a half-life of approximately 26 minutes — longer than Sermorelin, shorter than CJC-1295 DAC.
Regulatory status:
- FDA-approved November 2010 as Egrifta (500 μg/day subcutaneous) for HIV-associated lipodystrophy
- Reformulated as Egrifta SV (smaller injection volume) in subsequent years
- Egrifta WR (F8 formulation) approved March 2025 — improved formulation requiring only weekly reconstitution instead of daily [2]
- Developed and marketed by Theratechnologies (Montreal, Canada)
- Also investigated in clinical trials for NAFLD, cognitive function in HIV patients, and general metabolic health
This is a real prescription drug. The evidence base isn't research chemical speculation — it's Phase III trial data, FDA review, and decades of post-marketing surveillance in thousands of patients.
Tesamorelin mechanism of action: what it actually does in the body
The fundamental mechanism is classical GHRH receptor activation — the same pathway as Sermorelin, Mod GRF 1-29, and natural GHRH. What makes Tesamorelin clinically distinctive is the potency, duration, and specific effect on visceral fat.
At the pituitary:
- Subcutaneous injection → Tesamorelin enters circulation
- Binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells
- Activates adenylate cyclase → cAMP → PKA → GH release
- Stimulates pulsatile endogenous GH secretion
- Downstream IGF-1 elevation from liver and peripheral tissues
The visceral fat mechanism. Growth hormone has well-documented effects on lipolysis — breaking down fat for energy. The effect is particularly pronounced in visceral adipose tissue (VAT) — the metabolically dangerous deep abdominal fat surrounding internal organs. VAT is more lipolytically active than subcutaneous fat, richer in GH receptors, and more metabolically responsive to GH signaling. Tesamorelin's sustained physiological GH elevation preferentially mobilizes visceral fat while sparing subcutaneous fat and lean mass.
Clinical effect magnitude (LIPO-010 and LIPO-011 trials): 15-18% reduction in visceral adipose tissue over 26 weeks; effect sustained through 52 weeks with continued treatment; minimal effect on subcutaneous fat; no significant loss of lean mass; improvements in triglycerides and some lipid parameters; IGF-1 elevation into the upper normal range [3].
The key clinical distinction from HGH: Tesamorelin achieves meaningful visceral fat reduction while preserving the pulsatile, feedback-regulated pattern of natural GH release. HGH at doses that would match this effect size on VAT typically produces more side effects, feedback suppression, and larger safety concerns.
Who uses Tesamorelin and what for
FDA-approved indication:
- HIV-infected adults with lipodystrophy — the only approved use. Prescribed specifically for excess abdominal fat caused by antiretroviral-related fat redistribution.
Off-label uses with varying clinical justification:
- NAFLD/NASH/MASH — the strongest off-label evidence. Tesamorelin has been studied specifically for hepatic fat reduction, with published trials showing significant reductions in liver fat content [4]. Not FDA-approved for this indication but clinically promising.
- Metabolic syndrome with central obesity — used off-label for people with significant visceral fat problems, often those who've plateaued with diet, exercise, and GLP-1 agonists.
- Age-related body composition changes — the largest off-label user population. Middle-aged adults seeking to reduce visceral fat and improve body composition.
- Cognitive support in aging and HIV patients — some research suggests cognitive benefits, particularly in HIV populations.
- Athletes and bodybuilders during cutting phases — prohibited by sporting bodies but used off-label for visceral fat reduction during contest prep.
Realistic expectations over 6 months of treatment for visceral fat-focused applications: measurable reduction in waist circumference (typically 2-4 cm), visible reduction in abdominal protrusion particularly the "hard belly" pattern of visceral adiposity, 15-18% reduction in measured VAT on imaging, improved metabolic markers, modest improvements in subjective energy and sleep.
What WON'T happen: dramatic subcutaneous fat loss (Tesamorelin targets VAT, not subcutaneous fat), muscle gains like HGH would produce, effects comparable to GLP-1 agonists for general weight loss, rapid results (visceral fat reduction develops over 3-6 months), preserved effects after stopping (VAT tends to rebound over 6-12 months after discontinuation).
What Tesamorelin stacks with: popular combinations
- Tesamorelin + Ipamorelin — GHRH + GHRP combination. Adds ghrelin receptor activation to GHRH signaling for amplified GH pulse. Used in some clinics for combined body composition and anti-aging goals.
- Tesamorelin + Semaglutide or Tirzepatide — combining visceral fat targeting (Tesamorelin) with broader weight loss and appetite suppression (GLP-1 agonist). Powerful for severe metabolic syndrome cases but expensive.
- Tesamorelin + Testosterone replacement therapy — in men with confirmed hypogonadism, the combination addresses multiple dimensions of metabolic dysfunction.
- Tesamorelin + Metformin — complementary for insulin resistance and metabolic syndrome.
Generally not combined with: exogenous HGH (redundant — defeats the purpose of endogenous stimulation), other GHRH analogs (Sermorelin, Mod GRF 1-29, CJC-1295) — these target the same receptor.
Tesamorelin side effects and risks
Because Tesamorelin went through full FDA clinical trials, its side effect profile is extensively characterized. Side effects generally reflect the physiological elevation of GH and IGF-1.
Common side effects (from pivotal trials):
- Injection site reactions — redness, pain, pruritus. Very common, typically mild.
- Arthralgia and myalgia — joint and muscle pain, particularly during initial treatment
- Pain in extremity — commonly reported
- Peripheral edema — mild fluid retention, typically in ankles/hands
- Hypoesthesia (numbness) or paresthesia — tingling, particularly in hands
- Headache
- Nausea — less common than with GLP-1 agonists
Less common but important:
- Carpal tunnel-like symptoms — some patients develop wrist tingling/weakness that resolves with dose reduction
- Hypersensitivity reactions — including rare anaphylactic-type responses
- Glucose intolerance and hyperglycemia — GH effects on insulin sensitivity. Typically mild and dose-dependent.
Serious warnings (FDA labeling):
- Fluid retention — can worsen heart failure or cause new-onset heart failure in susceptible patients
- Hyperglycemia and diabetes — monitor glucose in diabetic patients
- IGF-1 elevation — needs monitoring to avoid supraphysiological levels
- Malignancy concerns — theoretical cancer concerns from GH/IGF-1 axis activation
Who should absolutely avoid:
- Pregnant or breastfeeding women (pregnancy category X — causes fetal harm in animal studies)
- Active malignancy (absolute contraindication)
- Hypersensitivity to tesamorelin or mannitol (excipient)
- Disrupted hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, pituitary tumors, or radiation
- Critical illness
Who should use with caution:
- Diabetics (monitor glucose closely)
- People with history of malignancy (theoretical concerns about GH/IGF-1 axis)
- Heart failure patients
- Anyone with proliferative retinopathy
- Competitive athletes — Tesamorelin is on the WADA Prohibited List (S2) [5]
How to use and store Tesamorelin
FDA-approved protocol (Egrifta SV / Egrifta WR):
- Standard dose: 1.4 mg (or 2 mg depending on formulation) subcutaneously once daily
- Subcutaneous injection in abdomen (rotate sites)
- Egrifta WR (F8): weekly reconstitution, daily injection. Smaller injection volume than earlier formulations.
- Egrifta SV (F4): daily reconstitution and injection.
Off-label protocols for body composition:
- Dose: 1-2 mg per day subcutaneously
- Frequency: once daily (matches approved protocol)
- Cycle: 3-6 months typical for visceral fat reduction; some clinicians continue longer with monitoring
- Timing: morning or evening; evening dosing sometimes preferred to align with natural GH nocturnal pulse
- Empty stomach: more important than most realize — food (especially carbohydrates) significantly blunts GH response
Important timing caveat: Tesamorelin's effect on visceral fat develops gradually over months. Three-month courses may show modest changes; meaningful visceral fat reduction typically requires 6 months. Anyone expecting 4-week transformations will be disappointed.
Storage: approved products have specific refrigeration and reconstitution requirements per product labeling. Research/compounded tesamorelin follows standard peptide storage — lyophilized at -20°C, reconstituted at 2-8°C, used within 30 days.
Labs and monitoring during Tesamorelin therapy
Before starting: IGF-1, fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel. Waist circumference and (ideally) CT or MRI measurement of visceral fat for baseline. For HIV patients: viral load, CD4 count, current antiretroviral regimen review.
During treatment (every 3-6 months): IGF-1 (target: upper normal range for age), fasting glucose, HbA1c, waist circumference, lipid panel.
After 6-12 months: reassess visceral fat reduction (ideally imaging), metabolic improvements, and decide on continuation. Stopping typically leads to gradual VAT regain over 6-12 months.
Tesamorelin vs alternatives: what's different
- Sermorelin / Mod GRF 1-29 / CJC-1295 — other GHRH analogs. Cheaper, less researched for body composition specifically, less potent for visceral fat reduction. Better choices for general anti-aging and physiological GH optimization.
- HGH (somatropin) — direct hormone replacement. More dramatic effects but more side effects, legal restrictions in US, non-pulsatile pattern with feedback suppression. Less favorable for VAT-specific goals.
- Semaglutide / Tirzepatide (GLP-1 agonists) — dramatic total weight loss (10-20%) with mixed effects on body composition. Better for general weight loss; less targeted for visceral fat specifically.
- AOD 9604 — fat-loss peptide fragment of GH. Much less effective than Tesamorelin for visceral fat specifically.
Tesamorelin's distinguishing feature: the only FDA-approved GHRH analog with specific indication for visceral fat reduction, backed by Phase III trial data showing 15-18% VAT reduction without muscle loss. For specifically targeting the dangerous deep abdominal fat while preserving lean mass, nothing else in the peptide space has comparable clinical validation.
Myths about Tesamorelin
- "Tesamorelin is the best GHRH analog for everyone." It's the most FDA-validated, but it's also the most expensive (approved brands can cost thousands per month without insurance coverage for off-label use) and specifically designed for visceral fat rather than broad GH optimization. For people without central adiposity concerns who want general anti-aging effects, Mod GRF 1-29 + Ipamorelin is cheaper and arguably more physiological.
- "Tesamorelin will make you lose weight like Ozempic." It specifically reduces visceral fat, not total body weight. Patients in trials typically lost 2-4 pounds total while losing 15-18% of visceral fat — because the fat loss was compensated somewhat by lean mass preservation and water retention. Anyone expecting scale-based weight loss will be disappointed even if the visceral fat reduction is clinically significant.
Sources
- Ferdinandi, E. S., Brazeau, P., High, K., Procter, B., Fennell, S., & Dubreuil, P. (2007). Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology, 100(1), 49-58. — foundational pharmacology paper on tesamorelin (TH9507).
- Theratechnologies Inc. (March 25, 2025). FDA Approves EGRIFTA WR™ (tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy. https://www.theratech.com/news-releases/news-release-details/theratechnologies-receives-fda-approval-egrifta-wrtm-tesamorelin/ — most recent FDA approval announcement for the improved F8 formulation.
- Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370. — landmark LIPO-010 Phase III trial establishing visceral fat reduction efficacy.
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., & Grinspoon, S. K. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 6(12), e821-e830. — key trial showing Tesamorelin's effect on NAFLD in HIV patients.
- World Anti-Doping Agency (WADA). Prohibited List — Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. https://www.wada-ama.org — Tesamorelin classification in competitive sport.
- Falutz, J., Potvin, D., Mamputu, J. C., Assaad, H., Zoltowska, M., Michaud, S. E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311-322. — LIPO-011 Phase III trial.
- U.S. Food and Drug Administration. Egrifta (tesamorelin) prescribing information and approval history. https://www.accessdata.fda.gov/ — official FDA approval documentation and labeling information.
- Clemmons, D. R., Miller, S., & Mamputu, J. C. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with generalized lipodystrophy: A pilot study. PLoS One, 12(6), e0179538. — extending tesamorelin investigation beyond HIV-specific lipodystrophy.
Tesamorelin Dosage Guide
Tesamorelin is a synthetic 44-amino-acid GHRH analog with a trans-3-hexenoyl modification at the N-terminus that enhances stability against enzymatic degradation. It binds the GHRH receptor on pituitary somatotroph cells, stimulating pulsatile endogenous growth hormone secretion and downstream hepatic IGF-1 production — with a particularly pronounced effect on visceral adipose tissue (VAT) that makes it distinct from other GHRH analogs. This guide is aimed at HIV patients with antiretroviral-associated lipodystrophy (the FDA-approved indication), metabolically unhealthy adults pursuing visceral fat reduction under medical supervision, and users targeting deep abdominal fat that hasn't responded to diet and exercise. Dosing below follows the FDA-approved Egrifta SV (2 mg) and Egrifta WR (1.28 mg) prescribing information, the LIPO-010 Phase 3 pivotal trials demonstrating 15–24% VAT reduction at 26 weeks, and the off-label longevity protocols that have emerged for non-HIV visceral fat applications.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Starter (sensitive users) | 1 mg | Once daily, SC abdomen | Lower end; titrate up after 2 weeks |
| FDA-approved (Egrifta SV) | 2 mg | Once daily, SC abdomen | Standard prescribing dose |
| FDA-approved (Egrifta WR) | 1.28 mg | Once daily, SC abdomen | Equivalent efficacy, higher concentration |
| Off-label standard | 2 mg | Once daily, SC abdomen | Non-HIV visceral fat protocols |
| Cycled off-label | 2 mg | Once daily 5 days on / 2 off | Some provider variations |
| Extended cycle | 2 mg | Once daily, 60–90 days on / 30 off | Off-label longevity protocols |
Doses also shift depending on the specific goal. The same peptide used for FDA-approved lipodystrophy versus off-label visceral fat reduction follows similar dosing but different cycling frameworks.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| HIV-associated lipodystrophy (FDA) | 2 mg (Egrifta SV) or 1.28 mg (Egrifta WR) | Once daily, SC abdomen | Continuous, long-term |
| Visceral fat reduction (off-label) | 2 mg | Once daily, SC abdomen | 6 months continuous, then reassess |
| Metabolic health / fatty liver | 2 mg | Once daily, SC abdomen | 26–52 weeks |
| Cognitive support research | 2 mg | Once daily, SC abdomen | 20 weeks (Baker MCI trial reference) |
| Stacked with Ipamorelin (off-label) | 1–2 mg Tesamorelin + 200 mcg Ipamorelin | Once daily, different injections | 12–16 weeks |
| Maintenance after cycle | 1–2 mg | 3–4 times weekly, SC abdomen | After initial 6-month loading |
Inject subcutaneously into the abdomen below the navel, rotating sites with each dose — do not inject into scar tissue, bruises, or the navel itself. Expect measurable VAT reduction at 8–12 weeks, with full clinical significance at 26 weeks (mean 15–24% reduction in Phase 3 trials). Critically, tesamorelin's effects are not retained after discontinuation — visceral fat reaccumulates within weeks of stopping, so this is a long-term therapy rather than a one-time intervention. Absolute contraindications include active cancer or any history of cancer that is not fully treated and inactive, pituitary gland tumor or prior pituitary surgery, head injury or radiation to the head, pregnancy (FDA Category X — can cause birth defects), breastfeeding, known hypersensitivity to tesamorelin or mannitol, and pediatric use in children with open growth plates. Monitor IGF-1 and glucose at baseline and every 6–8 weeks; tesamorelin reduces insulin sensitivity and can worsen glycemic control in diabetics and pre-diabetics.
Tesamorelin Storage Guide: How to Keep Your Research Peptide Stable and Effective
Tesamorelin ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its 44-amino-acid modified GHRH structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — protect from direct light and UV exposure to prevent photodegradation. | Keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Oxidation Sensitivity | Tesamorelin contains a methionine residue that's prone to oxidation if the vial seal is broken or the powder is exposed to air. | Keep the aluminum crimp cap intact until ready to reconstitute. |
| Signs of Degradation | Healthy powder is white to off-white and loose or cake-like. Watch for yellowing, browning, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a humid kitchen or bathroom, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — specifically a modified version of GRF(1-44) with a trans-3-hexenoic acid group added to the N-terminus, which dramatically improves its stability compared to natural GHRH. It is FDA-approved and sold under the brand names Egrifta, Egrifta SV, and most recently Egrifta WR, manufactured by Theratechnologies. It holds the distinction of being the only medication approved in the US specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It has been approved since 2010.
Tesamorelin binds to GHRH receptors on the pituitary gland, stimulating the body's natural release of growth hormone (GH). The increased GH then raises IGF-1 levels and, critically, triggers strong lipolysis (fat breakdown) specifically in visceral adipose tissue — the metabolically active fat that accumulates around internal organs in the abdomen. Unlike direct HGH injections, tesamorelin preserves the body's natural feedback regulation. Notably, it doesn't significantly affect subcutaneous fat (the fat just under the skin) — its action is selective for the more harmful visceral fat.
The only FDA-approved indication for tesamorelin is reducing excess abdominal fat in HIV-infected adults with lipodystrophy — a common side effect of antiretroviral therapy that causes fat to accumulate around the organs, raising cardiovascular and metabolic risk. Off-label, it is increasingly used in anti-aging and wellness clinics to reduce stubborn visceral fat, improve body composition, and support metabolic health in non-HIV patients. It's also being studied for NAFLD (fatty liver disease) and cognitive benefits in older adults, though these uses remain investigational.
The FDA-approved dose for the older Egrifta SV formulation is 2 mg injected subcutaneously into the abdomen once daily. The newer Egrifta WR (F8 formulation), approved in 2025, uses a more concentrated 1.28 mg once-daily dose — bioequivalent to the older 2 mg dose but requiring less than half the injection volume. Egrifta WR also only needs weekly reconstitution versus daily, making it significantly easier to use. Treatment is long-term — visceral fat often returns after discontinuation. Off-label wellness dosing sometimes uses lower amounts (1 mg daily) but should always be set by a clinician.
The most common side effects are joint pain (arthralgia), injection-site reactions, pain in the extremities, peripheral edema (swelling of hands and feet), muscle aches, numbness or tingling, and flushing. Because tesamorelin raises GH and IGF-1, it can cause mild glucose intolerance or worsen diabetes, so blood sugar monitoring is important. Rare but serious risks include increased intracranial pressure, worsening of existing tumors, and hypersensitivity reactions. Long-term cardiovascular safety has not been fully established.
Clinical trials showed meaningful visceral fat reduction at around 13 weeks (approximately 3 months), with continued improvement through 26 weeks. Average visceral fat reduction in HIV-lipodystrophy patients is around 15–18% over 6 months of daily use. Users typically notice improved energy, sleep quality, and a flatter abdominal profile before measurable fat loss on imaging. Importantly, visceral fat tends to return within weeks to months of stopping tesamorelin, which is why it is considered a long-term therapy rather than a short cycle.
Tesamorelin is not a general weight-loss drug and is not FDA-approved for weight management. It specifically targets visceral (deep abdominal) fat rather than total body weight, and it doesn't significantly affect subcutaneous fat, muscle mass, or appetite. Unlike GLP-1 drugs like semaglutide (Ozempic, Wegovy), which produce dramatic overall weight loss, tesamorelin produces more targeted body recomposition — a reduction in belly fat without much change on the scale. For people seeking general weight loss, GLP-1 drugs are far more effective; tesamorelin is better suited to those specifically trying to reduce stubborn visceral fat.
Tesamorelin is contraindicated in people with active malignancy (including hypothalamic or pituitary tumors), those with a history of disruption of the hypothalamic-pituitary axis, and during pregnancy and breastfeeding. Animal studies showed hydrocephalus in offspring at doses 2–4 times the clinical dose, so pregnancy prevention is essential. It should be used cautiously in people with diabetes due to its effect on glucose control, and in those with any acute critical illness. It is also not recommended for children with open or closed growth plates.
All three are GHRH analogs that stimulate natural growth hormone release, but they differ in potency, stability, and clinical profile. Sermorelin is the oldest — GHRH(1-29) — with a very short half-life of about 10–20 minutes, used mainly in anti-aging. Mod GRF (1-29) / CJC-1295 (no DAC) is a modified version with slightly better stability. Tesamorelin has the strongest clinical data specifically for visceral fat reduction in humans, and as an FDA-approved prescription drug it undergoes strict quality control. Tesamorelin is generally considered the most potent and clinically validated of the GHRH analogs for body composition.
Tesamorelin (Egrifta SV, Egrifta WR) is fully legal and FDA-approved as a prescription medication, available in regular pharmacies with a doctor's prescription. It's typically covered by insurance for its FDA-approved indication (HIV-associated lipodystrophy), though it's expensive — often $3,000+ per month out of pocket. For off-label use (anti-aging, body composition in non-HIV patients), coverage is rare and compounding pharmacies are commonly used at a lower cost. Research-grade tesamorelin is also sold online as "not for human consumption" — this exists in a legal grey zone and carries the usual purity and safety concerns of unregulated peptides. It is banned by WADA for competitive athletes.
